Financial Data and Key Metrics Changes - The company closed the year with a cash balance of $20.1 million and secured funding of $30.9 million in net proceeds [36] - A net loss of $14.1 million was reported, with a diluted loss per share of $0.17 [38] - Investment activities reduced from $52 million to $21 million, reflecting a shift from exploration to development [38] Business Line Data and Key Metrics Changes - The Kabanga Nickel Project is positioned as a development-ready asset with a $1.58 billion after-tax NPV and a strong 23.3% IRR, indicating competitive positioning against other nickel projects [12][13] - The feasibility study published in July 2025 confirmed the project's high quality and readiness for development [12] Market Data and Key Metrics Changes - Nickel prices have increased by $2,500 per ton since late 2025, positively impacting project financing and market interest [18] - The company is positioned to compete with Indonesia, which has a tightly controlled nickel market [4][13] Company Strategy and Development Direction - The strategic focus is on unlocking processing and refining bottlenecks in the supply chain, leveraging technological expertise in hydrometallurgy [6][7] - The company is pursuing partnerships for the Kabanga project and exploring opportunities in catalytic converter recycling [7][28] - Plans to develop a fully vertically integrated project in Tanzania, with a staged approach to downstream processing [54] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the project's potential and the importance of securing strategic partnerships to enhance shareholder value [56][70] - The company is committed to sustainability and differentiating its product as a cleaner alternative to nickel sourced from Indonesia [50] Other Important Information - The company has completed a life cycle assessment compliant with ISO standards, highlighting the project's environmental advantages [20] - A significant achievement includes the completion of the resettlement plan, which is crucial for obtaining a social license to operate [8] Q&A Session Summary Question: Will the nickel refinery from the Kabanga Project still be implemented in Tanzania after five years of mine operations? - The company plans to have a fully vertically integrated project in Tanzania, with a staged approach to downstream processes [54] Question: Will the potential partner join at a premium, and what will be the cost to own Musongati? - The current share price does not reflect the real value of the asset, and the company is focused on maximizing shareholder value [56] - The Musongati project is in early stages, with no capital committed until a proposal is developed [59] Question: What is the opinion on the recent decline in nickel prices, and what are the plans for FID? - Recent nickel price fluctuations are influenced by geopolitical events and changes in regulations in Indonesia [64] - The company is focused on securing strategic partnerships and financing options to progress towards FID [70]

Financial Data and Key Metrics Changes - For the fourth quarter, sales were $695.1 million, up 8.7% year-over-year, while organic sales decreased 0.1% excluding Stuart Weitzman [19] - Consolidated gross margin was 42.9%, down 10 basis points compared to the previous year, reflecting lower margins in the brand portfolio [20] - SG&A expenses increased by $48.3 million or 18.3% to $310 million, primarily driven by expenses related to Stuart Weitzman [21] - Fourth quarter earnings per diluted share were a loss of $0.36, while excluding Stuart Weitzman, the loss was $0.06 [22] Business Line Data and Key Metrics Changes - Brand portfolio sales increased 1.5% on an organic basis and 20.3% including Stuart Weitzman, with lead brands growing about 2% [5][19] - Famous Footwear sales decreased 1.2%, with comparable sales up 0.1%, showing slight improvement in November and December [20][12] - Sam Edelman and Allen Edmonds showed strong performance, with Sam Edelman exceeding expectations and Allen Edmonds experiencing broad-based growth across all channels [7][9] Market Data and Key Metrics Changes - The brand portfolio gained significant market share in both women's fashion footwear and total footwear during the quarter [6] - International business was strong, contributing positively to overall sales performance [5] - E-commerce continued to see outsized growth, particularly in owned channels, with double-digit growth reported [10][12] Company Strategy and Development Direction - The company views 2026 as a "build-back year," focusing on strategic growth vectors and initiatives already in place [5][16] - Plans to expand the FLAIR format in Famous Footwear, aiming for 65 to 75 locations by year-end 2026 [14] - The strategy includes elevating and editing the brand and product assortment, with a focus on premium brands [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about building market share and improving profitability, despite a volatile market environment [18] - The company is monitoring geopolitical risks and tariff changes, which could impact future performance [26] - Guidance for 2026 includes modest organic sales growth and meaningful earnings recovery, with expectations for consolidated sales to increase mid- to high single digits in Q1 [29] Other Important Information - The company successfully integrated Stuart Weitzman onto its platforms, completing the transition on time and on budget [8] - Inventory at quarter-end was $610.5 million, up $45 million from last year, with a portion attributed to Stuart Weitzman [25] Q&A Session Summary Question: Concerns about sales volatility and potential risks - Management noted that expected sales volatility did not materialize, with strong performance in other areas offsetting the impact from Saks [31][33] Question: Wholesale strategy and market share gains - Management indicated that the order book is in line with guidance, and they are prepared to move forward with their wholesale strategy [39][41] Question: Category performance and impact of external factors - Management highlighted strong performance in key brands and noted mixed results in Famous Footwear, with ongoing monitoring of external factors like weather and geopolitical issues [49][51] Question: Stuart Weitzman's break-even target - Management expressed confidence in achieving break-even for Stuart Weitzman in 2026, supported by completed cost-saving measures and inventory management [56][58]

Financial Data and Key Metrics Changes - Biofrontera achieved record annual revenues of $41.7 million in 2025, representing approximately 12% growth over the prior year [5][22] - Fourth quarter revenues reached $17.1 million, marking a 36% year-over-year increase and the highest quarterly revenue in the company's history [5][17] - Adjusted EBITDA for Q4 2025 was $4.9 million, a significant improvement from negative $1.4 million in Q4 2024 [21][27] - Net income for Q4 2025 was $5.6 million, compared to a net loss of $1.4 million in the same quarter of 2024 [21][26] Business Line Data and Key Metrics Changes - Ameluz unit volumes increased to approximately 121,000 tubes for the full year 2025, reflecting about 10% growth over 2024 [13] - Fourth quarter unit volumes were approximately 49,840 tubes, contributing to the strong revenue performance [13] - The installed base of RhodoLED lamps grew to approximately 745 across 686 dermatology offices by the end of 2025 [14] Market Data and Key Metrics Changes - The FDA accepted a supplemental new drug application for Ameluz in treating superficial basal cell carcinoma, with a PDUFA target action date of September 28, 2026 [9] - Positive phase 3 results were reported for actinic keratosis on the extremities, with plans to file a supplemental NDA in Q3 2026 [10] - The company anticipates a significant addressable market for treating extensive fields of actinic keratosis, affecting approximately 58 million American adults [10] Company Strategy and Development Direction - The completion of a strategic transaction with Biofrontera AG has fundamentally changed the business model, granting full control over U.S. assets and improving cost structure [7][40] - The new earn-out structure is expected to enhance gross margins, with projections of 80%-85% in 2026 [7][40] - The company is focused on expanding its clinical pipeline, with planned studies in squamous cell carcinoma and reduced pain PDT [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory, citing improved commercial execution and a strong pipeline of clinical developments [16][40] - The strategic transaction is expected to reduce cash consumption and advance towards cash flow breakeven [30][41] - Management highlighted the importance of institutional investors in supporting the company's strategic initiatives [30] Other Important Information - The company secured $11 million in funding through a private placement of Series C preferred stock [8] - A successful divestiture of the Xepi antibiotic cream license generated initial proceeds of $3 million, with potential additional milestone payments [8] Q&A Session Summary Question: Discussion on gross margin improvement for 2026 - Management expects gross profit margins to be between 80%-85%, starting from January 1, 2026, with potential fluctuations based on product mix [34][35]

Financial Data and Key Metrics Changes - The company closed the year with a cash balance of $20.1 million and secured funding of $30.9 million in net proceeds [36] - A net loss of $14.1 million was reported, with a diluted loss per share of $0.17 [38] - Investment activities reduced from $52 million to $21 million, reflecting a shift from exploration to development [38] Business Line Data and Key Metrics Changes - The Kabanga Nickel Project is positioned as a development-ready asset with a $1.58 billion after-tax NPV and a strong 23.3% IRR, indicating competitive positioning against other nickel projects [12][13] - The feasibility study published in July 2025 confirmed the project's superior quality and readiness for development [11][12] Market Data and Key Metrics Changes - Nickel prices have increased by $2,500 per ton since late 2025, positively impacting project financing and market interest [18] - The company is positioned to compete with Indonesia, which has a tightly controlled nickel market [4][13] Company Strategy and Development Direction - The strategic focus is on unlocking processing and refining bottlenecks in the supply chain, leveraging technological expertise in hydrometallurgy [6][7] - The company is pursuing partnerships for the Kabanga project and exploring additional projects like the catalytic converter recycling initiative with Glencore [7][29] - The Musongati project in Burundi is seen as a growth extension, capitalizing on synergies with the Kabanga project [32][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the project's potential and the importance of securing strategic partnerships to enhance shareholder value [56][70] - The company is committed to a staged approach for downstream processing, ensuring economic rationale and alignment with shareholder interests [54][55] Other Important Information - The company has completed a life cycle assessment compliant with ISO standards, highlighting the project's environmental advantages [20] - A significant amount of procurement processes valued at around $380 million has been initiated, demonstrating compliance with local content rules in Tanzania [21] Q&A Session Summary Question: Will the nickel refinery from the Kabanga Project still be implemented in Tanzania after five years of mine operations? - The company plans to have a fully vertically integrated project in Tanzania, with a staged approach to downstream processes [53][54] Question: Will the potential partner join at a premium, or are they happy with today's prices? - The current share price is not reflective of the asset's real value, and any strategic partnership will be at a more reflective long-term value [56][57] Question: What is the company's opinion on the recent continuous decline in nickel prices? - The decline in nickel prices is influenced by political events and changes in regulations in Indonesia, which have affected market dynamics [64][66]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was approximately $662 million, a 27.4% increase year-over-year. Full year 2025 revenue was approximately $2.433 billion, representing a 20.2% increase over the prior year [5][18] - Adjusted EBITDA for Q4 was $85 million, a 54% increase year-over-year, while full year 2025 Adjusted EBITDA was $320.8 million, a 74.8% increase [5][18] - Consolidated gross margin for Q4 was $213.3 million, or 32.2% [18] Business Line Data and Key Metrics Changes - Private Duty Services revenue for Q4 was approximately $541 million, a 28.1% increase, driven by 12.4 million hours of care, a volume increase of 17.9% [19] - Home Health and Hospice revenue for Q4 was approximately $69.3 million, a 27.3% increase, with 10,400 total admissions, 78% of which were episodic [21] - Medical Solutions revenue for Q4 was $52.5 million, up 21.3% year-over-year, with approximately 92,000 unique patients served [22] Market Data and Key Metrics Changes - Preferred payer agreements accounted for approximately 57% of total private duty services MCO volumes in Q4 [10] - The company achieved 10 rate enhancements in 2025, aligning with its government affairs strategy [8] - The episodic payer mix for home health was 78% in Q4, with total episodic volume growth of 25% year-over-year [11] Company Strategy and Development Direction - The company is focused on strengthening partnerships with government and preferred payers to create additional capacity and growth [16] - Strategic initiatives for 2026 include improving clinical outcomes, implementing AI and automation for operational efficiency, and pursuing acquisitions [16] - The company aims to add 8 additional preferred payer agreements in 2026, targeting a total of 38 agreements by year-end [10] Management's Comments on Operating Environment and Future Outlook - Management noted that the demand for home and community-based care remains strong, with no demand problem in the industry [6][7] - The company anticipates 2026 revenue in the range of $2.54-$2.56 billion and Adjusted EBITDA of $318-$322 million, considering ongoing challenges [17][26] - Management expressed confidence in the caregiver hiring and retention trends, which have improved due to alignment with preferred payers [7] Other Important Information - The company is in the process of acquiring Family First Homecare, expected to close in Q2 2026, which will enhance its service offerings in Florida [15][26] - The company had liquidity of approximately $529 million at the end of Q4, with cash on hand of approximately $193 million [24] Q&A Session Summary Question: Impact of Family First acquisition on leverage - Management indicated that the acquisition would have a minimal short-term impact on leverage, with expectations to slightly decrease leverage over 2026 due to generated free cash flow [29][30] Question: Geographic coverage of preferred provider arrangements - Management confirmed that the additional agreements in 2025 and anticipated agreements in 2026 are focused on densifying current geographies, with plans to fill in states like Ohio and Kentucky [32][34] Question: Revenue contribution from Family First - Management expects Family First to contribute approximately $120 million in revenue, with integration efforts anticipated to be smooth [38][39] Question: Trends in episodic mix and membership impacts - Management expressed confidence in maintaining an episodic mix above 75% and noted that they are not concerned about trends in managed Medicare [51] Question: California home-based nursing rates outlook - Management does not expect any material changes in California's budget for home-based nursing rates for 2026, indicating a challenging environment [64] Question: Travel reimbursement for caregivers - Management clarified that 80% of revenues are from shift care where mileage is not reimbursed, minimizing the impact of rising oil prices [72][73]

Financial Data and Key Metrics Changes - Biofrontera achieved record annual revenues of $41.7 million in 2025, representing a 12% growth over the prior year, with Q4 revenues of $17.1 million, a 36% year-over-year increase [5][18] - Adjusted EBITDA for Q4 2025 was $4.9 million, a significant improvement from negative $1.4 million in Q4 2024, reflecting a margin improvement to 29% from negative 11% [21][28] - The net income for Q4 2025 was $5.6 million, compared to a net loss of $1.4 million in Q4 2024, driven by higher revenues and lower costs [21][27] Business Line Data and Key Metrics Changes - Ameluz unit volumes increased significantly, with Q4 2025 unit volumes at approximately 49,840 tubes, bringing the full year total to about 121,000 tubes, a 10% increase over 2024 [14] - The installed base of RhodoLED lamps grew to approximately 745 across 686 dermatology offices by the end of 2025, with 85 new lamps placed during the year [15] Market Data and Key Metrics Changes - The new royalty structure for Ameluz is set at 12% for annual U.S. net sales at or below $65 million and 15% for sales exceeding that threshold, improving gross margins significantly [8][19] - The FDA accepted a supplemental new drug application for Ameluz to treat superficial basal cell carcinoma, with a target action date of September 28, 2026, representing a new commercial opportunity [10] Company Strategy and Development Direction - The completion of the strategic transaction with Biofrontera AG has fundamentally changed the business model, allowing full control over U.S. assets, intellectual property, and regulatory approvals [41] - The company plans to expand its clinical pipeline, with studies in squamous cell carcinoma in situ and reduced pain PDT, while patent protection extends through 2043 [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving gross profit margins between 80%-85% in 2026, driven by the new cost structure and improved operational efficiencies [35] - The company anticipates that the full annualized benefit of the new cost structure will be realized in 2026, contributing to a stronger financial trajectory [41] Other Important Information - Biofrontera secured $11 million in funding through a private placement of Series C preferred stock to support growth and the strategic transaction [9] - The company reported a significant reduction in related party cost of goods sold by 45% year-over-year, improving gross profit margins from 50% to 74% for the full year [24] Q&A Session Summary Question: Discussion on gross margin improvement for 2026 - Management expects gross profit margins to be between 80%-85% throughout 2026, starting at an 82% level [35] Question: Variability of gross margins over the year - Management indicated that while margins may fluctuate slightly based on product mix, they expect to maintain the target range consistently [36]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 reached $1.3 billion, representing a growth of 10.7% year-over-year, supported by a 16% increase in system-wide comparable sales [4] - Adjusted EBITDA for Q4 totaled $172.7 million, up 17.2% year-over-year, with an 80 basis points expansion in the adjusted EBITDA margin [4][12] - For the full year 2025, total revenue grew by almost 5% in US dollars, with adjusted EBITDA being the highest in the company's history [5][12] Business Line Data and Key Metrics Changes - In Brazil, comparable sales growth showed modest sequential improvement despite a challenging consumption environment, with a significant market share advantage maintained [9][10] - SLAD's comparable sales increased by 49.5% year-over-year, driven by strong execution in Argentina and other markets [11] - NOLAD experienced a 1.7% growth in comparable sales, with Mexico being the main contributor [10] Market Data and Key Metrics Changes - Digital channel penetration reached 62% of total sales, with digital channel sales growing 18.7% year-over-year [8] - The loyalty program had 27.2 million registered members at year-end, covering over 90% of all restaurants in the footprint [9] - The Brazilian real's strength contributed to revenue growth in US dollars during the quarter [10] Company Strategy and Development Direction - The company focuses on optimizing current business performance, maximizing returns on capital investments, and preparing for future business trends [3] - A disciplined approach to pricing, cost control, and marketing relevance has been emphasized, alongside investments in high-return restaurant development and digital capabilities [4] - The company plans to open 105-115 new restaurants in 2026, with total capital expenditures between $275 million and $325 million [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business momentum entering 2026, anticipating a more normalized consumer environment and continued profitability trends [21] - The company is focused on building healthy comparable sales while managing costs and maintaining market share [35] - Early results in 2026 have shown strong performance, with expectations for higher gross margins throughout the year [20] Other Important Information - The company opened 102 new restaurants in 2025, modernizing 73% of its portfolio by year-end [6] - A cash dividend of $0.28 per share has been declared for 2026, up from $0.24 the previous year [20] - The company implemented a G&A restructuring that reduced the ongoing cost base by more than $10 million annually [45] Q&A Session Summary Question: Can you explain the higher taxes paid during the quarter? - The effective tax rate for 2025 was 37.7%, an improvement of almost 5 percentage points versus 2024, with no structural changes expected for 2026 [26][27] Question: What are the drivers of margin expansion in Brazil and SLAD? - Brazil saw a small improvement in gross margin, with payroll expenses improving due to productivity gains, while SLAD experienced leverage in payroll and occupancy expenses [28][29] Question: Given the recent depreciation of LatAm currencies, how does this affect your outlook? - The Brazilian real and Mexican peso have appreciated, positively impacting results, with expectations for continued favorable currency performance [32][33] Question: How should we think about Brazil's comp sales throughout 2026? - The company expects to build healthy comparable sales, focusing on a combination of pricing and mix to offset volume declines [34] Question: Can you provide more details on the headcount reduction? - The G&A restructuring aimed to improve efficiency, resulting in a reduction of over $10 million in the annual cost base [45] Question: Why was CapEx for 2025 below initial guidance despite higher openings? - The company optimized capital spending while maintaining the planned number of openings, benefiting from localized suppliers and reduced per unit costs [47][48] Question: Are there signs of same-store sales recovery in the first quarter of 2026? - The company plans to deliver comparable sales growth in line with inflation levels, supported by a robust marketing plan [51]

Financial Data and Key Metrics Changes - The company closed the year with a cash balance of $20.1 million and secured funding of $30.9 million in net proceeds [38] - A net loss of $14.1 million was reported, with a diluted loss per share of $0.17 [39] - Investment activities reduced from $52 million to $21 million, reflecting a shift from exploration to development [40] Business Line Data and Key Metrics Changes - The Kabanga Nickel Project is positioned at the lower end of the cost curve, with a $1.58 billion after-tax NPV and a strong 23.3% IRR [13][14] - The company has engaged in several funding processes to reach a final investment decision (FID) for the Kabanga project, including a $60 million bridge facility from Taurus [11][16] Market Data and Key Metrics Changes - Nickel prices have increased by $2,500 per ton since late 2025, positively impacting project financing [20] - The nickel market is tightly controlled by Indonesia, which has influenced pricing and supply dynamics [68] Company Strategy and Development Direction - The company aims to unlock processing and refining bottlenecks in global supply chains, leveraging its hydrometallurgical expertise [7] - A partnership with Glencore on catalytic converter recycling is part of the company's growth strategy [30] - The company is exploring synergies between the Kabanga and Musongati projects to enhance economic potential [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic financing initiatives and the potential for long-term partnerships [16][17] - The company is committed to a staged approach for downstream processing, ensuring economic viability while building the mine [57] - Management highlighted the importance of sustainability and the project's lower CO2 emissions compared to competitors [55] Other Important Information - The company has completed a life cycle assessment compliant with ISO standards, showcasing the project's environmental advantages [22] - The acquisition of a 17% stake from BHP was completed, providing full control over the project direction and financing flexibility [44][46] Q&A Session Summary Question: Will the nickel refinery from the Kabanga Project still be implemented in Tanzania after five years of mine operations? - The company plans to have a fully vertically integrated project in Tanzania, with a staged approach to downstream processes [57] Question: Will the potential partner join at a premium, or are current prices acceptable? - The current share price is not reflective of the asset's real value, and any partnership will be at a more reflective valuation [60][61] Question: What is the status of the Musongati project? - The company is in the early stages of assessing the Musongati project and has committed to a reconnaissance scoping study [62][63] Question: What is the company's opinion on the recent decline in nickel prices? - The decline is influenced by geopolitical events and changes in regulations in Indonesia, which have affected market dynamics [68][69]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was approximately $662 million, a 27.4% increase year-over-year. Full year 2025 revenue was approximately $2.433 billion, representing a 20.2% increase over the prior year [4][18] - Adjusted EBITDA for Q4 was $85 million, a 54% increase year-over-year, while full year 2025 Adjusted EBITDA was $320.8 million, a 74.8% increase [4][18] - Consolidated gross margin for Q4 was $213.3 million, or 32.2% [18] Business Line Data and Key Metrics Changes - Private Duty Services revenue for Q4 was approximately $541 million, a 28.1% increase, driven by 12.4 million hours of care, a volume increase of 17.9% [19] - Home Health and Hospice revenue for Q4 was approximately $69.3 million, a 27.3% increase, with 10,400 total admissions, 78% of which were episodic [21] - Medical Solutions revenue for Q4 was $52.5 million, up 21.3% year-over-year, with approximately 92,000 unique patients served [22] Market Data and Key Metrics Changes - Preferred payer agreements accounted for approximately 57% of total private duty services MCO volumes in Q4 [10] - The company aims to increase the number of preferred payer agreements from 30 to 38 by the end of 2026 [10] Company Strategy and Development Direction - The company is focused on five primary strategic initiatives for 2026: strengthening partnerships with government and preferred payers, improving clinical outcomes, implementing AI and automation, growing through acquisitions, and engaging employees [16] - The acquisition of Family First Homecare is expected to close in Q2 2026, enhancing the company's service offerings in Florida [15][17] Management's Comments on Operating Environment and Future Outlook - Management noted that the demand for home and community-based care remains strong, with ongoing efforts to address labor market challenges [5][6] - The company anticipates 2026 revenue in the range of $2.54-$2.56 billion and Adjusted EBITDA between $318-$322 million, considering ongoing challenges in the operating environment [17][26] Other Important Information - The company achieved 10 rate enhancements in 2025, aligning with its government affairs strategy [8] - Cash generated by operating activities was $125.9 million, with free cash flow of $131 million for 2025 [25] Q&A Session Summary Question: Impact of Family First acquisition on leverage and margin contribution - Management expressed excitement about the acquisition, indicating minimal short-term impact on leverage and a plan to deleverage in 2026 [30][31] Question: Geographic coverage of preferred provider arrangements - Management confirmed that the additional agreements in 2025 and 2026 are focused on densifying current geographies, with plans to fill in states like Ohio and West Virginia [34][35] Question: Revenue contribution and KPIs from Family First - Expected revenue from Family First is around $120 million, with a focus on integration and leveraging existing payer relationships in Florida [40][41] Question: Trends in episodic mix and membership impacts - Management reported strong growth in episodic admissions and expressed confidence in the home health and hospice business despite membership volatility [51][52] Question: Travel reimbursement for caregivers and impact of fuel prices - Management clarified that 80% of revenues are from shift care with minimal impact from fuel prices, as most caregivers do not incur travel costs [74][75] Question: Replicating preferred payer strategy in home health - Management highlighted the success of the episodic payer mix strategy and the importance of clinical outcomes in driving payer relationships [81][82]

Financial Data and Key Metrics Changes - For the fourth quarter, sales were $695.1 million, up 8.7% year-over-year, while organic sales decreased 0.1% excluding Stuart Weitzman [19] - Consolidated gross margin was 42.9%, down 10 basis points from the previous year, reflecting lower margins in the brand portfolio [20] - SG&A expenses increased by $48.3 million or 18.3% to $310 million, primarily due to expenses related to Stuart Weitzman [21] - Fourth quarter earnings per diluted share were a loss of $0.36, while excluding Stuart Weitzman, the loss was $0.06 [23] Business Line Data and Key Metrics Changes - Brand portfolio sales increased 1.5% on an organic basis and 20.3% including Stuart Weitzman, with lead brands growing about 2% [5][19] - Famous Footwear sales decreased 1.2%, with comparable sales up 0.1% [20] - Sam Edelman and Allen Edmonds showed strong performance, with Sam Edelman exceeding expectations and Allen Edmonds experiencing broad-based growth across all channels [9][10] Market Data and Key Metrics Changes - The brand portfolio gained significant market share in both women's fashion footwear and total footwear during the quarter [5] - Famous Footwear saw market share gains driven by strong performance from brands like Skechers and Jordan during the holiday season [45] Company Strategy and Development Direction - The company aims to build back earnings power in 2026, focusing on strategic growth vectors and initiatives already in place [5] - Plans to expand the FLAIR format at Famous Footwear, with expectations to increase locations from 57 to a range of 65-75 by year-end 2026 [13] - The company is committed to elevating and editing brand and product assortments to enhance consumer experience [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026 as a build-back year, with expectations of modest organic sales growth and meaningful earnings recovery [16] - The company is monitoring geopolitical risks and tariff changes, which could impact future performance [27] - Management noted that the integration of Stuart Weitzman is on track and is expected to contribute positively to profitability [60] Other Important Information - The company ended the fourth quarter with $282.9 million in cash and $296.5 million in borrowings, with inventory at $610.5 million [26] - The company is maintaining a flexible approach to sourcing amid evolving tariff environments [27] Q&A Session Summary Question: Concerns about sales volatility and tax impacts - Management acknowledged that expected sales volatility did not materialize, with strong performance in other business areas offsetting minor impacts [34] Question: Wholesale planning and market share gains - Management indicated that the order book is in line with guidance, and they are seeing positive trends in e-commerce and international sales [43] Question: Category performance and sandal sales - Management reported strong sales in sandals, particularly from brands like Birkenstock and Crocs, and noted good performance in the thong category [57] Question: Stuart Weitzman break-even expectations - Management confirmed that significant cost-saving measures have been implemented, positioning Stuart Weitzman to return to break-even in 2026 [60]